Attached files
EXHIBIT 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
(18 U.S.C. SECTION 1350)
In
connection with the Annual Report of Aeolus Pharmaceuticals, Inc.
(the “Company”) on Form 10-K/A for the period ended
September 30, 2016, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), the
undersigned, John L. McManus, Principal Executive Officer of the
Company, and David Cavalier, Principal Financial and Accounting
Officer of the Company, each certify pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that, to the best of his knowledge:
1.
The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and
2.
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company
for the period covered by the Report.
Date: January 30,
2017
/s/ John L. McManus
John L.
McManus
President and Chief
Executive
Officer
(Principal
Executive
Officer)
Date: January 30,
2017
/s/ David C. Cavalier
David
C. Cavalier
Chairman, Chief
Financial Officer and
Secretary
(Principal
Financial and Accounting
Officer)
THIS
CERTIFICATION “ACCOMPANIES” THE ANNUAL REPORT, IS NOT
DEEMED FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AND IS NOT
TO BE INCORPORATED BY REFERENCE INTO ANY FILING OF THE COMPANY
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED (WHETHER MADE BEFORE OR AFTER THE
DATE OF THE ANNUAL REPORT), IRRESPECTIVE OF ANY GENERAL
INCORPORATION LANGUAGE CONTAINED IN SUCH FILING. A SIGNED ORIGINAL
OF THIS CERTIFICATION HAS BEEN PROVIDED TO THE COMPANY AND WILL BE
RETAINED BY THE COMPANY AND FURNISHED TO THE SECURITIES AND
EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.